| Primary |
| Pneumonia |
11.3% |
| Sepsis |
10.4% |
| Tuberculosis |
9.4% |
| Antibiotic Therapy |
7.5% |
| Acute Lymphocytic Leukaemia |
6.6% |
| Cystic Fibrosis |
5.7% |
| Mycobacterium Abscessus Infection |
4.7% |
| Pulmonary Tuberculosis |
4.7% |
| Antiretroviral Therapy |
3.8% |
| Bartholinitis |
3.8% |
| Lung Infection |
3.8% |
| Mycobacterial Infection |
3.8% |
| Staphylococcal Infection |
3.8% |
| Urinary Tract Infection |
3.8% |
| Acute Myeloid Leukaemia |
2.8% |
| Blood Culture Positive |
2.8% |
| Bronchopneumonia |
2.8% |
| Febrile Neutropenia |
2.8% |
| Infection |
2.8% |
| Meningitis Bacterial |
2.8% |
|
| Candida Sepsis |
11.6% |
| Acute Generalised Exanthematous Pustulosis |
7.0% |
| Death |
7.0% |
| Drug Ineffective |
7.0% |
| Neutropenic Colitis |
7.0% |
| Thrombocytopenia |
7.0% |
| Dyspnoea |
4.7% |
| Enterocolitis |
4.7% |
| Mycobacterial Infection |
4.7% |
| Mycobacterium Abscessus Infection |
4.7% |
| Neutropenia |
4.7% |
| Renal Failure Acute |
4.7% |
| Renal Impairment |
4.7% |
| Restlessness |
4.7% |
| Tubulointerstitial Nephritis |
4.7% |
| Back Pain |
2.3% |
| Deafness |
2.3% |
| Depression |
2.3% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
2.3% |
| Grand Mal Convulsion |
2.3% |
|
| Secondary |
| Pneumonia |
16.7% |
| Drug Use For Unknown Indication |
13.4% |
| Pyrexia |
12.7% |
| Sepsis |
9.3% |
| Product Used For Unknown Indication |
7.2% |
| Bacteraemia |
4.5% |
| Acute Myeloid Leukaemia |
4.0% |
| Febrile Neutropenia |
3.6% |
| Infection Prophylaxis |
3.4% |
| Hypertension |
2.7% |
| Mediastinal Abscess |
2.7% |
| Retroperitoneal Abscess |
2.7% |
| B-cell Lymphoma |
2.2% |
| Lung Disorder |
2.2% |
| Septic Shock |
2.2% |
| Abscess |
2.1% |
| Antifungal Prophylaxis |
2.1% |
| Bronchopulmonary Aspergillosis |
2.1% |
| Hiv Infection |
2.1% |
| Lung Abscess |
2.1% |
|
| White Blood Cell Disorder |
10.7% |
| Renal Impairment |
9.3% |
| Vomiting |
8.0% |
| Wheezing |
8.0% |
| Pyrexia |
6.7% |
| Toxic Epidermal Necrolysis |
6.7% |
| Deafness |
5.3% |
| Thrombocytopenia |
5.3% |
| Liver Disorder |
4.0% |
| Neutropenia |
4.0% |
| Rash |
4.0% |
| Septic Shock |
4.0% |
| Transaminases Increased |
4.0% |
| White Blood Cell Count Decreased |
4.0% |
| Cerebellar Syndrome |
2.7% |
| Depression |
2.7% |
| Dermatitis Exfoliative |
2.7% |
| Hepatic Failure |
2.7% |
| Hepatotoxicity |
2.7% |
| Jaundice |
2.7% |
|
| Concomitant |
| Drug Use For Unknown Indication |
19.6% |
| Prophylaxis |
14.8% |
| Hiv Infection |
12.5% |
| Product Used For Unknown Indication |
10.6% |
| Infection Prophylaxis |
7.5% |
| Mycobacterium Avium Complex Infection |
4.4% |
| Aplastic Anaemia |
3.9% |
| Acute Myeloid Leukaemia |
3.4% |
| Pneumonia |
2.8% |
| Bone Marrow Conditioning Regimen |
2.6% |
| Prophylaxis Against Graft Versus Host Disease |
2.4% |
| Antifungal Prophylaxis |
2.3% |
| Cytomegalovirus Infection |
2.2% |
| Hypertension |
1.9% |
| Stem Cell Transplant |
1.7% |
| Pyrexia |
1.6% |
| Infection |
1.5% |
| Premedication |
1.5% |
| Allogenic Bone Marrow Transplantation Therapy |
1.5% |
| Febrile Neutropenia |
1.5% |
|
| Vomiting |
15.1% |
| White Blood Cell Count Decreased |
14.3% |
| Pyrexia |
7.8% |
| Sepsis |
7.3% |
| Septic Shock |
6.5% |
| Liver Disorder |
4.5% |
| Stomatitis |
4.5% |
| Pneumonia |
4.1% |
| Weight Increased |
4.1% |
| Venoocclusive Liver Disease |
3.7% |
| Respiratory Failure |
3.3% |
| Retinal Haemorrhage |
3.3% |
| Shock |
3.3% |
| Staphylococcal Infection |
3.3% |
| Pseudomembranous Colitis |
2.9% |
| Infection |
2.4% |
| Platelet Count Decreased |
2.4% |
| Renal Impairment |
2.4% |
| Small Intestinal Perforation |
2.4% |
| Syncope |
2.4% |
|
| Interacting |
| General Anaesthesia |
100.0% |
|
| Potentiating Drug Interaction |
100.0% |
|
